Soluble ST2: A new and promising activity marker in ulcerative colitis

Table 4 Baseline serum sST2 levels according to clinical characteristics of patients

	Serum sST2 (pg/mL), median (Percentiles 25th-75th)
	UC	Non-IBD	HC
Gender
Female	55.5 (29.3-150.1)	43.9 (22.1-73.1)	29.4 (17.0-40.3)
Male	99.7 (34.0-216.4)	59.7 (35.6-74.9)	36.2 (27.0-53.2)
Age (yr)
18-24	190.8 (52.6-489.6)	63.2 (31.7-74.9)	29.0 (17.0-45.0)
25-34	66.2 (30.4-313.3)	46.3 (18.5-116.6)	32.4 (16.9-40.8)
35-44	125.4 (37.0-182.9)	48.1 (32.2-67.8)	44.3 (27.9-59.6)
45-54	48.2 (24.9-116.4)	43.6 (26.0-72.4)	51.0 (35.7-65.0)
≥ 55	51.3 (19.9-90.5)	53.0 (25.9-78.8)	0
Location of disease
Ulcerative proctitis, E1	56.5 (22.4-141.6)
Left-sided colitis, E2	35.8 (19.4-66.2)
Extensive colitis, E3	110.2 (34.0-345.8)a
Medication at endoscopy
No medication	36.4 (19.6-105.6)
Topical 5-ASA	39.7 (20.4-75.7)
Systemic 5-ASA	59.0 (23.6-141.7)
Systemic steroids	242.4 (124.9-349.1)a
5-ASA + steroids	125.4 (50.0-417.9)
5-ASA + azathioprine	41.1 (68.9-109.0)
Azathioprine	0

^aP≤ 0.05 vs other groups in the analysis. UC: Ulcerative colitis; HC: Healthy subjects; IBD: Inflammatory bowel disease; 5-ASA: 5-aminosalicylic acid derivatives.